SOX2 autoantibodies as noninvasive serum biomarker for breast carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 11, 2012, Pages 2043-2047

  Sun, Yu ^a,c   Zhang, Rui ^a,c   Wang, Minjie ^b   Zhang, Yuan ^a,c   Qi, Jun ^b   Li, Jinming ^a,c  

^a GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

^b CANCER HOSPITAL   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TRANSCRIPTION FACTOR SOX2;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST DISEASE; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; NON INVASIVE PROCEDURE; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK FACTOR;

ANTIBODIES, NEOPLASM; AUTOANTIBODIES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; SOXB1 TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84869223955     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0498     Document Type: Article

References (19)

1. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312. (Pubitemid 350232263)
2. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008;283:17969-78.
3. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2012;31:1354-65.
4. Lengerke C, Fehm T, Kurth R, Neubauer H, Scheble V, Müller F, et al. Expression of the embryonic stem cell marker SOX2 in early-stage breast cancer. BMC Cancer 2011;11:42-51.
5. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, Hernandez L, et al. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 2007;20:474-81. (Pubitemid 46482371)
6. Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, Hegeman IM, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009;27:4260-7.
7. Güre AO, Stockert E, Scanlan MJ, Keresztes RS, Jäger D, Altorki NK, et al. Serological identifi cation of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A 2000;97:4198-203. (Pubitemid 30226110)
8. Chapman CJ, Thorpe AJ, Murray A, Parsy-Kowalska CB, Allen J, Stafford KM, et al. Immunobiomarkers in small cell lung cancer: potential early cancer signals. Clin Cancer Res 2011;17:1474-80.
9. Vural B, Chen LC, Saip P, Chen YT, Ustuner Z, Gonen M, et al. Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer 2005;103:2575-83. (Pubitemid 40800537)
10. Maddison P, Thorpe A, Silcocks P, Robertson JF, Chapman CJ. Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. Lung Cancer 2010;70:335-9.
11. Comtesse N, Zippel A, Walle S, Monz D, Backes C, Fischer U, et al. Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci U S A 2005;102:9601-6. (Pubitemid 40981727)
12. Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, Vesole D, et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 2007;204:831-40. (Pubitemid 46631612)
13. Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels BM, et al. Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation. Clin Dev Immunol 2011;2011:302145-54.
14. Li W, Wang W, Sun S, Sun Y, Pan Y, Wang L, et al. Autoantibodies against the catalytic domain of BRAF are not specific serum markers for rheumatoid arthritis. PLoS One 2011;6:e28975-80.
15. Gnjatic S, Old LJ, Chen YT. Autoantibodies against cancer antigens. Methods Mol Biol 2009;520:11-9.
16. Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008;7:1388-94.
17. Blixt O, Bueti D, Burford B, Allen D, Julien S, Hollingsworth M, et al. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res 2011;13:R25-40.
18. Kobold S, Luetkens T, Cao Y, Bokemeyer C, Atanackovic D. Prognostic and diagnostic value of spontaneous tumor-related antibodies. Clin Dev Immunol 2010;2010:721531-8.
19. Megliorino R, Shi FD, Peng XX, Wang X, Chan EK, Tan EM, et al. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev 2005;29:241-8. (Pubitemid 40779801)